Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 18;41(6):3292–3304. doi: 10.3892/or.2019.7131

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — USP9X regulates MMP9 and p-DRP1 through the ERK signaling pathway. (A) Western blotting demonstrated that USP9X-knockdown upregulated the levels of p-ERK. No changes were observed for p-AKT and p-p65. (B) PD98059 treatment inhibited ERK phosphorylation in the prostate cancer cell lines, and decreased MMP9 and p-DRP1 protein levels. The inhibitor PD98059 abolished the effect of USP9X silencing on the levels of MMP9 and p-DRP1. ^#P<0.05, *P<0.05 vs. untreated siControl and ^§P<0.05 vs. PD98059-treated siControl using analysis of variance with a least-significant-difference post hoc test. The data are presented as the mean ± standard deviation. USP9X, ubiquitin-specific protease 9X; MMP9, matrix metalloproteinase 9; DRP1, dynamin-related protein 1; p-, phosphorylated; ERK, extracellular signal-regulated kinase; AKT, protein kinase B; p65, transcription factor p65; siUSP9X, siRNA targeting the USP9X gene; siControl, control siRNA.

Figure 5. — USP9X regulates MMP9 and p-DRP1 through the ERK signaling pathway. (A) Western blotting demonstrated that USP9X-knockdown upregulated the levels of p-ERK. No changes were observed for p-AKT and p-p65. (B) PD98059 treatment inhibited ERK phosphorylation in the prostate cancer cell lines, and decreased MMP9 and p-DRP1 protein levels. The inhibitor PD98059 abolished the effect of USP9X silencing on the levels of MMP9 and p-DRP1. ^#P<0.05, *P<0.05 vs. untreated siControl and ^§P<0.05 vs. PD98059-treated siControl using analysis of variance with a least-significant-difference post hoc test. The data are presented as the mean ± standard deviation. USP9X, ubiquitin-specific protease 9X; MMP9, matrix metalloproteinase 9; DRP1, dynamin-related protein 1; p-, phosphorylated; ERK, extracellular signal-regulated kinase; AKT, protein kinase B; p65, transcription factor p65; siUSP9X, siRNA targeting the USP9X gene; siControl, control siRNA.